Loading organizations...
Translate Bio has raised $136.0M across 3 funding rounds.
Key people at Translate Bio.
Translate Bio has raised $136.0M in total across 3 funding rounds.
Translate Bio is a clinical-stage messenger RNA (mRNA) therapeutics company focused on developing new medicines for diseases stemming from protein or gene dysfunction and for preventing infectious diseases by generating protective immunity. The company's technology applies broadly, including a proprietary platform for pulmonary diseases, with a lead candidate in development for cystic fibrosis, alongside other discovery programs such as mRNA vaccines.
Founded in 2010 as RaNA Therapeutics, the company was established by Arthur Krieg and Jeannie T. Lee, M.D., Ph.D., in collaboration with Atlas Venture. Their foundational insight centered on leveraging novel approaches to transcriptional activation to create a new class of mRNA-based treatments designed to address underlying genetic causes of illness.
The company's products aim to serve patients with debilitating and life-threatening conditions, particularly those affected by rare genetic disorders impacting protein or gene function, as well as individuals vulnerable to infectious diseases. Translate Bio's vision involves fully realizing the therapeutic potential of mRNA technology to deliver transformative treatments and preventative health solutions for a wide range of significant medical challenges.
Translate Bio has raised $136.0M across 3 funding rounds. Most recently, it raised $51.0M Series C in January 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2017 | $51M Series C | — | Atlas Venture | Announced |
| Jul 1, 2015 | $64M Series B | Baupost Group, Joshua Resnick | Atlas Venture, Dcvc (data Collective), Brookside Capital, Leerink Partners, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Rock Springs Capital, SR ONE | Announced |
| Jan 1, 2012 | $21M Series A | Atlas Venture, Stephen Padgette, Brian Gallagher, JR. | Dcvc (data Collective), Partners Innovation Fund | Announced |
Translate Bio has raised $136.0M in total across 3 funding rounds.
Translate Bio's investors include Atlas Venture, Baupost Group, Joshua Resnick, DCVC (Data Collective), Brookside Capital, Leerink Partners, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Rock Springs Capital, SR One.
Translate Bio is a clinical‑stage messenger RNA (mRNA) therapeutics company that developed an mRNA platform for treating protein- or gene‑dysfunction diseases and for creating vaccines; it was acquired by Sanofi in 2021 and now operates within Sanofi's mRNA efforts[4][1].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick reprise: Translate Bio built an mRNA platform focused on therapeutic protein expression and vaccines with a distinctive pulmonary delivery emphasis, and its 2021 acquisition by Sanofi transferred that platform and clinical programs into a large‑scale effort to extend mRNA beyond infectious‑disease vaccines[4][1].
Key people at Translate Bio.